2430-01-5

Usage

Uses

Used in Pharmaceutical Synthesis:
2-bromo-N,N-diethyl-acetamide is utilized as an intermediate in the production of pharmaceuticals, contributing to the development of new medications and therapeutic agents. Its unique chemical properties allow for its integration into complex molecular structures, enhancing the efficacy and functionality of resulting pharmaceutical compounds.
Used in Agrochemical Production:
In the agrochemical industry, 2-bromo-N,N-diethyl-acetamide serves as a key intermediate, aiding in the synthesis of various agrochemicals designed to protect crops and enhance agricultural productivity. Its role in this sector underscores its versatility and importance in creating effective solutions for pest control and crop management.
Used as a Reagent in Organic Synthesis:
2-bromo-N,N-diethyl-acetamide is employed as a reagent in organic synthesis, facilitating the formation of new chemical bonds and the creation of novel organic compounds. Its reactivity and stability make it a valuable tool in the synthesis of a wide range of organic molecules.
Used in the Preparation of Functionalized Compounds:
As a building block, 2-bromo-N,N-diethyl-acetamide is instrumental in the preparation of various functionalized compounds. Its ability to be incorporated into different chemical frameworks allows for the development of specialized materials with tailored properties for specific applications across various industries.

InChI:InChI=1/C6H12BrNO/c1-3-8(4-2)6(9)5-7/h3-5H2,1-2H3

Upstream product

• 109-89-7 diethylamine 
• 598-21-0 2-Bromoacetyl bromide 
• 79-08-3 bromoacetic acid 
• 22118-09-8 2-bromoacetyl chloride 
• 39096-01-0 N,N-diethyl-2-hydroxyacetamide 
• 7087-68-5 N-ethyl-N,N-diisopropylamine 
• 2315-36-8 2-Chloro-N,N-diethylacetamide 

Downstream Products

• 67971-12-4 3-hydroxy-3,3-diphenyl-propionic acid diethylamide 
• 5450-73-7 (1-hydroxy-cyclohexyl)-acetic acid diethylamide 
• 25290-18-0 N,N-diethyl-3-hydroxy-3-phenylpropionamide 
• 71037-00-8 (N,N-dicarbamoylmethyl) diphenyldithiophosphinate 
• 10385-09-8 N,N-diethyl nonanamide 
• 137653-90-8 (E)-N,N-Diethyl-3-pentafluorophenyl-acrylamide 
• 2602-61-1 N,N-diethyldecanamide 
• 27829-46-5 (E)-N,N-diethyl-3-phenylacrylamide 
• 118282-59-0 2-(4-tert-Butyl-1-hydroxy-cyclohexyl)-N,N-diethyl-acetamide 
• 163019-28-1 N,N-diethyl-2-phenylsulfonylacetamide 
• 330455-95-3 3-(N,N-diethylcarbamoylmethyl)-1-mesitylimidazolium bromide 
• 289687-05-4 tert-butyl 4-[N-[7-chloro-3-diethylcarbamoylmethyl-4-oxo-2-piperidin-1-ylmethyl-3,4-dihydroquinazolin-6-ylmethyl]-N-(prop-2-ynyl)amino]benzoate 
• 50507-86-3 Diethylamide of p-nitrophenylacetic acid 
• 51764-13-7 N,N-diethyl-3,3-diphenyl-2-propenamide 

Relevant academic research and scientific papers

A new facile synthesis of a thromboxane B2 precursor

A short, stereocontrolled synthesis of a key intermediate in the synthesis of thromboxane B2 is described. The approach is based on the use of N,N-diethyl(phenylsulfonyl)acetamide as nucleophile in a palladium-catalysed nucleophilic substitutio

Probing phenylcarbamoylazinane-1,2,4-triazole amides derivatives as lipoxygenase inhibitors along with cytotoxic, ADME and molecular docking studies

Hunting small molecules as anti-inflammatory agents/drugs is an expanding and successful approach to treat several inflammatory diseases such as cancer, asthma, arthritis, and psoriasis. Besides other methods, inflammatory diseases can be treated by lipoxygenase inhibitors, which have a profound influence on the development and progression of inflammation. In the present study, a series of new N-alkyl/aralky/aryl derivatives (7a-o) of 2-(4-phenyl-5-(1-phenylcarbamoyl)piperidine-4H-1,2,4-triazol-3-ylthio)acetamide was synthesized and screened for their inhibitory potential against the enzyme 15-lipoxygenase. The simple precursor ethyl piperidine-4-carboxylate (a) was successively converted into phenylcarbamoyl derivative (1), hydrazide (2), semicarbazide (3) and N-phenylated 5-(1-phenylcarbamoyl)piperidine-1,2,4-triazole (4), then in combination with electrophiles (6a-o) through further multistep synthesis, final products (7a-o) were generated. All the synthesized compounds were characterized by FTIR, 1H, 13C NMR spectroscopy, EIMS, and HREIMS spectrometry. Almost all the synthesized compounds showed excellent inhibitory potential against the tested enzyme. Compounds 7c, 7f, 7d, and 7g displayed potent inhibitory potential (IC50 9.25 ± 0.26 to 21.82 ± 0.35 μM), followed by the compounds 7n, 7h, 7e, 7a, 7b, 7l, and 7o with IC50 values in the range of 24.56 ± 0.45 to 46.91 ± 0.57 μM. Compounds 7c, 7f, 7d exhibited 71.5 to 83.5% cellular viability by MTT assay compared with standard curcumin (76.9%) when assayed at 0.125 mM concentration. In silico ADME studies supported the drug-likeness of most of the molecules. In vitro inhibition studies were substantiated by molecular docking wherein the phenyl group attached to the triazole ring was making a π-δ interaction with Leu607. This work reveals the possibility of a synthetic approach of compounds in relation to lipoxygenase inhibition as potential lead compounds in drug discovery.

Facile peripheral modification of N-confused porphyrin

An improved methodology for the N-alkylation of the porphyrin isomer N-confused porphyrin is presented. The combination of polar solvent conditions and the use of the base Cs2CO3 affords externally modified products in high yield wit

Identification of phenylcarbamoylazinane-1,3,4-oxadiazole amides as lipoxygenase inhibitors with expression analysis and in silico studies

In search for new anti-inflammatory agents that inhibit the enzymes of arachidonic acid pathway as the drug targets, the present article describes the screening of 1,3,4-oxadiazole analogues against lipoxygenase (LOX) enzyme. The work is based on the synthesis of new N-alkyl/aralky/aryl derivatives (6a-o) of 2-(4-phenyl-5-(1-phenylcarbamoylpiperidine)-4H-1,3,4-oxadiazol-3-ylthio)acetamide which were obtained by the reaction of 1,3,4-oxadiazole (3) with various electrophiles (5a-o), in KOH. The synthesized analogues showed potent to moderate inhibitory activity against the soybean 15-LOX enzyme; especially 6g, 6b, 6a and 6l displayed the potent inhibitory potential with IC50 values 7.15 ± 0.26, 9.32 ± 0.42, 15.83 ± 0.45 & 18.37 ± 0.53 μM, respectively, while excellent to moderate inhibitory profiles with IC50 values in the range of 26.13–98.21 μM were observed from the compounds 6k, 6m, 6j, 6o, 6h, 6f, 6n and 6c. Most of the active compounds exhibited considerable cell viability against blood mononuclear cells (MNCs) at 0.25 mM by MTT assay except 6f, 6h, 6k and 6m which showed around 50% cell viability. Flow cytometry studies of the selected compounds 6a, 6j and 6n revealed that these caused 79.5–88.51% early apoptotic changes in MNCs compared with 4.26% for control quercetin at their respective IC50 values. The relative expression of 5-LOX gene was monitored in MNCs after treatment with these three molecules and all down-regulated the enzyme activity. In silico ADME and molecular docking studies further supported these studies of oxadiazole derivatives and considered it as potential ‘lead’ compounds in drug discovery and development.

Quaternary ammonium salt type honokiol/magnolol derivative as well as preparation method and application thereof

The invention discloses a series of novel quaternary ammonium salt honokiol/magnolol derivatives as well as a preparation method and application thereof. According to the series of compounds, honokiol/magnolol is taken as a raw material, a series of novel quaternary ammonium salt honokiol/magnolol derivatives are prepared on phenolic hydroxyl groups of honokiol/magnolol through a coupling reaction, and the structural general formula is shown in the specification. The compound disclosed by the invention has very strong antibacterial activity on staphylococcus aureus ATCC 29213 and clinically separated methicillin-resistant staphylococcus aureus (MRSA), most of the derivatives are higher than parent honokiol/magnolol, and the activity of part of the target derivatives is higher than that of a contrast drug levofloxacin. The compound is expected to be used for preparing drugs for resisting staphylococcus aureus and methicillin-resistant staphylococcus aureus.

Copper-catalyzed oxyvinylation of diazo compounds

A copper(I)-catalyzed vinylation of diazo compounds with vinylbenziodoxolone reagents (VBX) as partners is reported. The transformation tolerates diverse functionalities on both reagents delivering polyfunctionalized vinylated products. The strategy was successfully extended to a three-component/intermolecular version with alcohols. The obtained products contain synthetically versatile functional groups, such as an aryl iodide, an ester, and an allylic leaving group, enabling further modification.

Design, Synthesis, Antimicrobial Evaluation, and Laccase Catalysis Effect of Novel Benzofuran–Oxadiazole and Benzofuran–Triazole Hybrids

Novel structural hybrids of benzofuran–oxadiazole and benzofuran–triazole have been synthesized and evaluated for their potential against Staphylococcus aureus, Bacillus subtilis, and Escherichia coli. The excellent antibiotic activity was shown by compou

Novel potential pyrazolopyrimidine based translocator protein ligands for the evaluation of neuroinflammation with PET

Translocator protein (TSPO) is an interesting biological target because TSPO overexpression is associated with microglial activation caused by neuronal damage or neuroinflammation, and these activated microglia are involved in several central nervous syst

Organosilicon Reducing Reagents for Stereoselective Formations of Silyl Enol Ethers from α-Halo Carbonyl Compounds

Salt-free stereoselective synthesis of silyl enol ethers was achieved by treating α-halo carbonyl compounds with 2,3,5,6-tetramethyl-1,4-bis(trimethylsilyl)-1,4-dihydropyrazine. In this reaction, easily removable trimethylsilyl halides and 2,3,5,6-tetramethylpyrazine were generated as the reaction byproducts. Due to the inertness of the reaction byproducts, we found a one-pot transformation of the in situ generated silyl enol ethers into various α-functionalized carbonyls by reaction with Togni-II reagent or aldehydes.

Enantioselective Spirocyclopropanation of para-Quinone Methides Using Ammonium Ylides

The use of Cinchona alkaloid-based chiral ammonium ylides allows for the first highly enantioselective and broadly applicable spirocyclopropanation reactions of para-quinone methides. This strategy provides a straightforward protocol toward the chiral spiro[2.5]octa-4,7-dien-6-one skeleton, which is a frequently found structural motif in important biologically active molecules.